This review identifies MAPK pathways' role in myocardial fibrosis, suggesting potential therapies for cardiovascular diseases.
Myocardial fibrosis (MF) is a hallmark pathological outcome of many cardiovascular diseases and a key component of cardiac remodeling. The p38 MAPK, JNK, and ERK signaling pathways are central to this process. This review summarizes the roles and interactions of these factors in MF and identifies relevant drug and non-pharmacological therapies targeting these pathways.
No takes yet. Share an insight, caveat, or question.
Wu et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: